logo
Share SHARE
FONT-SIZE Plus   Neg

Santarus Says FDA Accepts Application Seeking Approval For Colon Drug Uceris

Biopharmaceutical company Santarus, Inc. (SNTS) on Wednesday said the United States Food and Drug Administration has accepted for filing its new drug application for Uceris tablets indicated for treatment of inflammatory bowel disease.

With the application, or NDA, the company seeks approval to market Uceris (budesonide) tablets 9 mg in the U.S. as a therapy to induce remission of mild to moderate active ulcerative colitis. The company anticipates the completion of the FDA's review or a response to the NDA by mid-October 2012.

Santarus will now pay $4 million to the co-developer of the drug, Cosmo Technologies Limited, a unit of Japan's Cosmo Pharmaceuticals S.p.A, in cash or Santarus stock at Cosmo's option.

Ulcerative colitis is a form of inflammatory bowel disease that produces inflammation and ulcers along the inside of the colon that could cause cramping, bloating, diarrhea, bleeding, fatigue, weight loss and frequent bowel movements. According to the Crohn's & Colitis Foundation of America, the chronic relapsing-remitting illness affects an estimated 1.4 million Americans.

Gerald Proehl, president and chief executive officer, stated, "Ulcerative colitis is a serious, chronic disease that typically starts to manifest in young adults with a long-term negative impact on the patient. We look forward to the potential to offer what we believe will be an important new therapeutic option to physicians and their patients to manage the symptoms of active ulcerative colitis."

Santarus shares closed Tuesday's regular trading session at $4.80, down $0.12 or 2.44 percent.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Bank of Nova Scotia or otherwise known as Scotiabank, Friday reported lower net profit for the third quarter, in the absence of a year-ago gain. Earnings per share, however, came in line with the Street view. Further, the company said it raised its quarterly dividend by 2 cents. Non-traditional discount and variety stores operator Big Lots Inc. (BIG) Friday reported a decline in net profit for the second quarter, while net sales grew 1.2 percent from the prior year. Comparable sales for the quarter increased 2.8 percent. Google has rejected the European Union's charges that it abused its market power and the demanded that it change the way it ranks online comparison shopping services in its search results, setting up a potentially long legal battle with the EU regulator empowered to levy billions of euros in fines
comments powered by Disqus
Follow RTT